α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response

Yoshihiko Tachi, Takanori Hirai, Youji Ishizu, Takashi Honda, Teiji Kuzuya, Kazuhiko Hayashi, Masatoshi Ishigami, Hidemi Goto

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

Background and Aims:: Eradicating chronic hepatitis C virus (HCV) infection improves liver fibrosis and reduces hepatocellular carcinoma (HCC) incidence in chronic HCV patients. We evaluated the relationship between fibrosis regression, as assessed by sequential biopsies, and clinical factors of patients with sustained virological response (SVR). Methods:: We retrospectively enrolled 130 patients (74 men; 60.1±8.1years) with chronic HCV treated with interferon and ribavirin therapy who achieved SVR. To evaluate the change in fibrosis stage over time, all patients underwent a pre-therapy initial biopsy and a second biopsy after achieving SVR. Results:: The mean time between biopsies was 5.5±1.2years. Fibrosis stage regressed in 55 patients (42.3%), remained stable in 69 (53.1%), and progressed in 6 (4.6%). The mean fibrosis stage significantly decreased, from 2.01±0.99 units to 1.61±1.24 units (P<0.001). Aspartate aminotransferase, γ-glutamyltransferase, and α-fetoprotein (AFP) levels at 24weeks after the end of treatment (EOT) were significantly lower, and the platelet count at 24weeks after the EOT was significantly higher in patients with fibrosis regression than in those without. Logistic regression analysis confirmed that lower AFP levels (<5.4ng/mL) at 24weeks after the EOT (odds ratio [OR], 4.626; 95% confidence interval [CI], 1.557-13.153; P=0.006) and HCV genotype 2 (OR, 2.198; 95% CI, 1.010-4.786; P=0.047) were significant independent predictive factors for regressed fibrosis after SVR. Conclusions:: Lower post-treatment AFP levels and HCV genotype 2 significantly correlated with liver fibrosis regression after SVR.

Original languageEnglish
Pages (from-to)1001-1008
Number of pages8
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume31
Issue number5
DOIs
Publication statusPublished - 01-05-2016
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Fingerprint

Dive into the research topics of 'α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response'. Together they form a unique fingerprint.

Cite this